Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


One-fifth of Zantac 75 U.S. sales came "at the expense" of Rx Zantac, Glaxo tells analysts.

This article was originally published in The Tan Sheet

Executive Summary

ONE-FIFTH OF ZANTAC 75 SALES CAME "AT THE EXPENSE" OF Rx ZANTAC, Glaxo Wellcome CEO Richard Sykes told securities analysts in New York City on Aug. 1. Commenting on the "success of Zantac 75," Sykes noted that the H2 antagonist is "rapidly going past Tagamet HB [and] approaching now the level of Pepcid AC." However, Sykes noted, "some of that growth has come at the expense of prescription Zantac sales."





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts